SPDR S&P Biotech ETF (NYSEArca: XBI)
January Gain: 17.5%
Comment: XBI has backed off the all-time highs it set earlier this month, but that has not been enough to keep the equal weight biotech ETF from being 2014’s top non-leveraged ETF. Some biotech investors remember that XBI was the lone sector ETF with any exposure to Intercept Pharmaceuticals (NasdaqGM: ICPT), the stock that surged over $200 in a single session last month. That put the spotlight on XBI and the ETF gained further acclaim for its small and mid-cap exposure, indicating the ETF is home to a swath of potential takeover targets. [Tiny Stocks Could Mean Big Gains for This Biotech ETF]